What it is claimed to help
These are the uses attached to PT-141 in research, clinical practice, or marketing. Listing a claim is not endorsing it — tap any of them to see every other compound carrying the same claim.
What the human evidence actually is
Approved by the FDA with randomised human trial data behind the label.
Real, and worth reading honestly. The RECONNECT trials led to FDA approval in 2019 for hypoactive sexual desire disorder in premenopausal women. The effect size was statistically significant and clinically modest. Development for erectile dysfunction was abandoned earlier over blood pressure increases with intranasal dosing.
How it is supposed to work
Non-selective melanocortin receptor agonist acting centrally at MC4R on sexual desire pathways — a brain mechanism, not a vascular one like PDE5 inhibitors.
Safety
Nausea is very common. Transient blood pressure increase and heart rate reduction; contraindicated in uncontrolled hypertension or known cardiovascular disease. Focal hyperpigmentation with repeated use.
Storage and handling
Lyophilised peptide is generally stored at 2–8 °C, or below −20 °C for long-term storage. Reconstituted in bacteriostatic water (0.9% benzyl alcohol) a solution is typically treated as usable for about 28 days refrigerated, versus roughly 24 hours for plain sterile water, which has no preservative. Add the water slowly down the vial wall and swirl — never shake, which shears peptide chains and foams the solution.
Whatever number a protocol or a prescriber gave you, converting it into syringe units is where a misplaced decimal becomes a tenfold error. Our calculators do that conversion and nothing else — they never invent a dose.
Open the calculatorsSources
- FDA prescribing information, Vyleesi
- Kingsberg SA et al. RECONNECT trials, Obstetrics & Gynecology 2019
Verified against primary sources on 27 August 2026. Regulatory status in this field changes several times a year. See How We Rate Evidence.